About AcuamarkDx
AcuamarkDx is a company based in New York (United States) founded in 2013.. AcuamarkDx has raised $20.01 million across 4 funding rounds from investors including Bruker and Claudio Del Vecchio. AcuamarkDx offers products and services including qPCR Cancer Assay. AcuamarkDx operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acuamark Diagnostics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.01 M (USD)
in 4 rounds
-
Latest Funding Round
$4.94 M (USD), Series A
May 22, 2024
-
Investors
Bruker
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AcuamarkDx
AcuamarkDx offers a comprehensive portfolio of products and services, including qPCR Cancer Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for detecting early-stage cancer markers in blood samples.
Funding Insights of AcuamarkDx
AcuamarkDx has successfully raised a total of $20.01M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.94 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $4.9M
-
First Round
First Round
(16 Nov 2016)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series A - AcuamarkDx | Valuation |
investors |
|
| Jul, 2022 | Amount | Series A - AcuamarkDx | Valuation | Claudio Del Vecchio | |
| Sep, 2019 | Amount | Seed - AcuamarkDx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AcuamarkDx
AcuamarkDx has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include Bruker and Claudio Del Vecchio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified research instrument systems are manufactured and supplied.
|
Founded Year | Domain | Location | |
|
CD
Claudio Del Vecchio |
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AcuamarkDx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AcuamarkDx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acuamarkdx Comparisons
Competitors of AcuamarkDx
AcuamarkDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Provider of DNA sequencing for cancer detection
|
|
| domain | founded_year | HQ Location |
Provider of cell-free cancer liquid biopsy test
|
|
| domain | founded_year | HQ Location |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| domain | founded_year | HQ Location |
MicroRNA profiling platform is developed to detect genes in samples.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acuamarkdx
Frequently Asked Questions about AcuamarkDx
When was AcuamarkDx founded?
AcuamarkDx was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Where is AcuamarkDx located?
AcuamarkDx is headquartered in New York, United States. It is registered at New York, New York, United States.
Is AcuamarkDx a funded company?
AcuamarkDx is a funded company, having raised a total of $20.01M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.29M, raised on Nov 16, 2016.
What does AcuamarkDx do?
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
Who are the top competitors of AcuamarkDx?
AcuamarkDx's top competitors include Guardant Health, GRAIL and BillionToOne.
What products or services does AcuamarkDx offer?
AcuamarkDx offers qPCR Cancer Assay.
Who are AcuamarkDx's investors?
AcuamarkDx has 2 investors. Key investors include Bruker, and Claudio Del Vecchio.